CA2021942C - Couplage d'un agent anti-tumoral a un anticorps au moyen d'une glytaraldehyde preactivee - Google Patents

Couplage d'un agent anti-tumoral a un anticorps au moyen d'une glytaraldehyde preactivee Download PDF

Info

Publication number
CA2021942C
CA2021942C CA002021942A CA2021942A CA2021942C CA 2021942 C CA2021942 C CA 2021942C CA 002021942 A CA002021942 A CA 002021942A CA 2021942 A CA2021942 A CA 2021942A CA 2021942 C CA2021942 C CA 2021942C
Authority
CA
Canada
Prior art keywords
daunorubicin
glutaraldehyde
antibody
conjugate
doxorubicin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002021942A
Other languages
English (en)
Other versions
CA2021942A1 (fr
Inventor
Michel Page
Denis Thibeault
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioxel Pharma Inc
Original Assignee
Bioxel Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioxel Pharma Inc filed Critical Bioxel Pharma Inc
Publication of CA2021942A1 publication Critical patent/CA2021942A1/fr
Application granted granted Critical
Publication of CA2021942C publication Critical patent/CA2021942C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6853—Carcino-embryonic antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CA002021942A 1989-08-10 1990-07-25 Couplage d'un agent anti-tumoral a un anticorps au moyen d'une glytaraldehyde preactivee Expired - Lifetime CA2021942C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39192889A 1989-08-10 1989-08-10
US391,928 1989-08-10

Publications (2)

Publication Number Publication Date
CA2021942A1 CA2021942A1 (fr) 1991-02-11
CA2021942C true CA2021942C (fr) 2001-04-10

Family

ID=23548555

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002021942A Expired - Lifetime CA2021942C (fr) 1989-08-10 1990-07-25 Couplage d'un agent anti-tumoral a un anticorps au moyen d'une glytaraldehyde preactivee

Country Status (2)

Country Link
CA (1) CA2021942C (fr)
WO (1) WO1991001757A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19636889A1 (de) 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5843926A (ja) * 1981-09-08 1983-03-14 Suntory Ltd 選択性制癌剤
GB2116979B (en) * 1982-02-25 1985-05-15 Ward Page Faulk Conjugates of proteins with anti-tumour agents
JPS59134732A (ja) * 1983-01-21 1984-08-02 Green Cross Corp:The フイブロネクチン・生理活性物質複合体の製造法
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
US4650675A (en) * 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates

Also Published As

Publication number Publication date
CA2021942A1 (fr) 1991-02-11
WO1991001757A1 (fr) 1991-02-21

Similar Documents

Publication Publication Date Title
US5208323A (en) Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent
US4699784A (en) Tumoricidal methotrexate-antibody conjugate
KR960015398B1 (ko) 신규의 링커를 갖는 안트라사이클린 면역결합체 및 그의 제조방법
AU767394B2 (en) Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
ES2623017T3 (es) Procedimiento para la preparación de una formulación medicamentosa inyectable
US4401592A (en) Pharmaceutical composition having antitumor activity
US4046722A (en) Immunological materials
US5004606A (en) Non-covalent antibody-anthracycline immunocomplexes
FI98197C (fi) Menetelmä sytotoksisten aineiden kasvainsoluihin toimittamiseen käyttökelpoisen vasta-aine-entsyymikonjugaatin valmistamiseksi
PT99954B (pt) Processo de preparacao de moleculas de ligacao labeis aos acidos e de composicoes farmaceuticas
KR20160045146A (ko) 마크롤라이드 디아스테레오머를 포함하는 약제학적 조성물, 이의 합성 방법 및 치료학적 용도
EA010508B1 (ru) Способ прицельного воздействия на определенные популяции клеток с помощью конъюгатов из майтансиноида и агента клеточного связывания, соединенных через нерасщепляемый линкер, конъюгаты и способы получения таких конъюгатов
US5514794A (en) Antibody-drug conjugates
DE102005009084A1 (de) Proteinbindende Anthrazyklin-Peptid-Derivate und diese enthaltende Arzneimittel
US4485093A (en) Immunotoxin conjugate which comprises arsanilic acid, useful for treating malignant tumors, particularly pancreatic cancer
KR20220038601A (ko) 캄토테신 약물 및 그의 항체 접합체
KR900017597A (ko) 신규의 링커를 갖는 안트라사이클린 결합체 및 그의 제조방법
CA2101809A1 (fr) Conjugues de drogues cytotoxiques pour le traitement des neoplasies
CA2021942C (fr) Couplage d'un agent anti-tumoral a un anticorps au moyen d'une glytaraldehyde preactivee
CN114053426A (zh) 一种双药链接组装单元及双药靶向接头-药物偶联物
RU2106147C1 (ru) Конъюгат производного 14-бромдаунорубицина с моноклональным антителом или его фрагментом, обладающий противоопухолевой активностью и имеющий специфичность к данной опухоли, и фармацевтическая композиция, обладающая противоопухолевой активностью
Wilchek Affinity therapy and polymer bound drugs
HU221857B1 (hu) Eljárás antraciklin-konjugátumok és ilyen vegyületeket tartalmazó gyógyászati készítmények előállítására
CN113941007B (zh) 一种串联的双药物链接组装单元及其应用
Sweet et al. Daunorubicin conjugated to a monoclonal anti-CA125 antibody selectively kills human ovarian cancer cells

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry